IGFBP6 and hepatocellular carcinoma: In one antibody-array study, circulating IGFBP-6 showed only a modest decrease in patients with HCC (mean ~15%) than in those with chronic hepatitis, and this signal was not validated by an orthogonal quantitative assay [111].